Suppliers and packagers for generic pharmaceutical drug: TECHNETIUM TC-99M TETROFOSMIN KIT

TECHNETIUM TC-99M TETROFOSMIN KIT

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Medi-physics	MYOVIEW	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372	NDA	Medi-Physics Inc. dba GE Healthcare	17156-024-05	5 VIAL in 1 KIT (17156-024-05) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	1996-02-09
Medi-physics	MYOVIEW	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372	NDA	Medi-Physics Inc. dba GE Healthcare	17156-026-30	5 VIAL in 1 KIT (17156-026-30) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2009-02-26
Medi-physics	MYOVIEW 30ML	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372	NDA	Medi-Physics Inc. dba GE Healthcare	17156-024-05	5 VIAL in 1 KIT (17156-024-05) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	1996-02-09
Medi-physics	MYOVIEW 30ML	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372	NDA	Medi-Physics Inc. dba GE Healthcare	17156-026-30	5 VIAL in 1 KIT (17156-026-30) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2009-02-26

TECHNETIUM TC-99M TETROFOSMIN KIT: GLOBAL SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

The global supply chain for Technetium Tc-99m Tetrofosmin Kit is characterized by a limited number of manufacturers holding key regulatory approvals. The production of Technetium Tc-99m, a crucial radioisotope for diagnostic imaging, is dependent on a small number of aging nuclear reactors, creating inherent supply vulnerabilities. Tetrofosmin, a radiopharmaceutical agent, is compounded and distributed by specialized pharmaceutical companies.

WHO ARE THE KEY MANUFACTURERS AND DISTRIBUTORS?

The primary manufacturers of Technetium Tc-99m Tetrofosmin Kit are a concentrated group of radiopharmaceutical companies with established Good Manufacturing Practice (GMP) certifications and extensive regulatory approvals from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• GE HealthCare: A dominant player in the radiopharmaceutical market, GE HealthCare manufactures and distributes Myoview, a Technetium Tc-99m Tetrofosmin-based imaging agent. Their supply chain benefits from significant vertical integration and a broad global distribution network.
• Cardinal Health: While primarily a distributor, Cardinal Health plays a crucial role in the logistics and delivery of radiopharmaceuticals, including Technetium Tc-99m Tetrofosmin Kit, to healthcare facilities. They manage the complex cold chain requirements for these temperature-sensitive products.
• Other Regional Suppliers: A number of smaller, regional suppliers exist, often holding specific national or localized regulatory approvals. Their market share is typically smaller, and their reliance on specific Tc-99m generators can be a factor in their supply stability. Examples may include companies like Positron Emission Tomography Limited (PET) or various radiopharmacies that compound doses from bulk materials.

The manufacturing process involves the sterile preparation of the tetrofosmin ligand and its packaging into a kit. This kit is then used at the point of care to elute Technetium Tc-99m from a Technetium-99m generator and prepare the final radiopharmaceutical for injection.

WHAT ARE THE PRIMARY SOURCES OF TECHNETIUM-99M?

The availability of Technetium-99m (Tc-99m) is the foundational element for the production of Technetium Tc-99m Tetrofosmin Kit. Tc-99m is a byproduct of the decay of Molybdenum-99 (Mo-99), which is produced in nuclear reactors.

• Nuclear Reactors: The global supply of Mo-99 is largely dependent on a few aging research reactors. Key facilities that have historically produced Mo-99 include:
  • NRU (National Research Universal), Chalk River, Canada: Historically a major supplier, its operational status has been intermittent due to maintenance and safety concerns. [1]
  • HFR (High Flux Reactor), Petten, Netherlands: A significant contributor to the global Mo-99 supply.
  • BR2, Mol, Belgium: Another important European source of Mo-99.
  • OPAL (Open Pool Australian Light water Reactor), Lucas Heights, Australia: Contributes to regional supply.
  • Polatom, Poland: Operates a reactor that produces Mo-99.

The aging infrastructure of these reactors presents a persistent risk of supply disruptions due to scheduled or unscheduled maintenance, or potential decommissioning. [2] Efforts have been made to diversify Mo-99 production through initiatives like the Global Medical Isotope Supply Chain Program, but these are ongoing. [3]

• Mo-99/Tc-99m Generators: Hospitals and radiopharmacies receive Mo-99 in the form of Mo-99/Tc-99m generators. Tc-99m is eluted from these generators for use in diagnostic procedures. The shelf life of these generators is typically short (e.g., 1-2 weeks), requiring regular and reliable delivery.

WHAT ARE THE KEY REGULATORY CONSIDERATIONS FOR SUPPLIERS?

Suppliers of Technetium Tc-99m Tetrofosmin Kit must adhere to stringent regulatory requirements to ensure product safety, efficacy, and quality. These regulations impact manufacturing, packaging, distribution, and post-market surveillance.

• Good Manufacturing Practice (GMP): All manufacturing facilities must comply with GMP standards set by regulatory bodies like the FDA (21 CFR Part 210 & 211) and the EMA (EudraLex Volume 4). This includes strict controls over raw materials, manufacturing processes, quality control, and documentation.
• Radiopharmaceutical Regulations: Specific regulations govern the handling, manufacturing, and distribution of radioactive materials. In the U.S., this falls under the purview of the Nuclear Regulatory Commission (NRC) and the FDA. In Europe, the European Nuclear Safety Regulators' Association (ENSRA) and national competent authorities are involved.
• Product Registration and Approval: Each market requires specific product registration and approval. For the Technetium Tc-99m Tetrofosmin Kit, this involves submitting detailed dossiers demonstrating quality, safety, and efficacy. Key approvals include:
  • FDA New Drug Application (NDA) or Abbreviated New Drug Application (ANDA): Required for products marketed in the United States.
  • EMA Marketing Authorisation Application (MAA): Required for products marketed in the European Union.
  • National Health Authority Approvals: For markets outside the U.S. and EU, approvals from respective national health ministries or regulatory agencies are necessary.
• Transportation of Radioactive Materials: The shipment of radiopharmaceuticals is subject to strict international and national regulations governing the transport of dangerous goods, including specific packaging, labeling, and documentation requirements (e.g., International Air Transport Association - IATA, Department of Transportation - DOT regulations).

WHAT ARE THE CRITICAL SUPPLY CHAIN CHALLENGES AND RISKS?

The supply chain for Technetium Tc-99m Tetrofosmin Kit faces several critical challenges and risks that can lead to shortages and impact patient care.

• Dependence on Aging Nuclear Reactors: The primary risk stems from the reliance on a small number of aging nuclear reactors for Mo-99 production. Unplanned shutdowns, maintenance outages, or eventual decommissioning of these reactors can lead to immediate and significant global Mo-99 shortages, which directly affect Tc-99m availability. [4]
  • Example: The prolonged shutdown of Canada's NRU reactor in 2016 caused widespread Mo-99 shortages, impacting the availability of various Tc-99m-based radiopharmaceuticals, including Tetrofosmin. [5]
• Limited Number of Manufacturers: The radiopharmaceutical industry is concentrated, with a few major players dominating the market. This lack of competition means that any disruption at one of these key manufacturers can have a widespread impact.
• Cold Chain Integrity: Technetium Tc-99m has a very short half-life of approximately 6 hours. This necessitates strict temperature control throughout the supply chain, from manufacturing to delivery to the end-user. Any failure in the cold chain can render the product unusable, leading to waste and shortages.
• Regulatory Hurdles for New Entrants: The high cost and complexity of establishing GMP-compliant manufacturing facilities and obtaining regulatory approvals for radiopharmaceuticals act as significant barriers to entry for new suppliers. This limits the overall resilience of the supply chain.
• Geopolitical and Logistical Factors: International shipping disruptions, geopolitical instability, and trade policies can also impact the timely and cost-effective delivery of both raw materials and finished products. The reliance on air cargo for time-sensitive shipments makes the supply chain vulnerable to flight cancellations and cargo restrictions.
• Security of Radioactive Materials: The handling and transport of radioactive isotopes require robust security measures to prevent diversion or misuse, adding complexity and cost to the supply chain.

WHAT ARE THE MARKET TRENDS AND FUTURE OUTLOOK?

The market for Technetium Tc-99m Tetrofosmin Kit is influenced by diagnostic imaging trends, regulatory developments, and advancements in radiopharmaceutical technology.

• Growing Demand for Diagnostic Imaging: The increasing incidence of cardiovascular diseases and cancer drives the demand for diagnostic imaging procedures, which in turn supports the market for radiopharmaceuticals like Tetrofosmin. [6]
• Technological Advancements: While Tc-99m remains the most widely used medical radioisotope, research into alternative imaging modalities and radioisotopes continues. However, the established infrastructure and cost-effectiveness of Tc-99m are likely to ensure its continued dominance in the short to medium term.
• Efforts to Diversify Mo-99 Production: Governments and industry bodies are investing in initiatives to establish more diverse and resilient sources of Mo-99, including the development of non-reactor-based production methods (e.g., using accelerators). [7] Successful implementation of these technologies could mitigate the risks associated with reactor dependence.
• Supply Chain Resilience Strategies: Manufacturers and distributors are increasingly focused on supply chain resilience, including maintaining higher inventory levels of critical components, developing contingency plans for reactor outages, and forging strategic partnerships to ensure continuity of supply.
• Consolidation in the Industry: The high capital investment and regulatory burden may lead to further consolidation within the radiopharmaceutical manufacturing sector, potentially concentrating supply even further.

Key Takeaways

The supply chain for Technetium Tc-99m Tetrofosmin Kit is critically dependent on a limited number of nuclear reactors for its Mo-99 precursor and a concentrated group of radiopharmaceutical manufacturers. The aging infrastructure of these reactors represents the most significant risk to supply continuity, exacerbated by the short half-life of Tc-99m and stringent regulatory requirements. Efforts to diversify Mo-99 production and enhance supply chain resilience are underway but face substantial technical and financial challenges.

FAQs

1. What is the primary reason for potential shortages of Technetium Tc-99m Tetrofosmin Kit? The primary reason is the reliance on a small number of aging nuclear reactors for the production of Molybdenum-99 (Mo-99), the precursor to Technetium-99m (Tc-99m). Unplanned outages or maintenance at these reactors can immediately disrupt the global supply of Mo-99, leading to Tc-99m shortages.

2. How is the short half-life of Technetium-99m managed in the supply chain? The short half-life (approximately 6 hours) necessitates a highly efficient and integrated supply chain. This involves rapid production, stringent cold chain management (maintaining low temperatures), and just-in-time delivery to hospitals and radiopharmacies.

3. Are there alternative radiotracers to Tetrofosmin for myocardial perfusion imaging? Yes, other radiotracers are used for myocardial perfusion imaging, including Technetium Tc-99m Sestamibi (e.g., Cardiolite) and Thallium-201. However, Tetrofosmin is a widely established and utilized agent.

4. What measures are being taken to improve the long-term stability of Tc-99m supply? Initiatives are underway to diversify Mo-99 production by exploring non-reactor-based methods, such as using accelerators. Additionally, efforts are focused on improving the reliability of existing reactors and developing strategies for more robust supply chain management.

5. Can new companies easily enter the market to manufacture Technetium Tc-99m Tetrofosmin Kit? No, new market entry is challenging due to the significant capital investment required for GMP-compliant manufacturing facilities, the complex regulatory approval processes, and specialized expertise needed for handling radioactive materials.

Citations

[1] Health Canada. (2018). Nuclear Research and Development Information. Retrieved from https://www.canada.ca/en/health-canada/corporate/about-health-canada/research-innovation/scientific-advisory-boards-committees/nuclear-research-development.html

[2] Organisation for Economic Co-operation and Development Nuclear Energy Agency. (2018). Medical Isotope Production: Ensuring Future Supply. OECD Publishing.

[3] U.S. Department of Energy Office of Nuclear Energy. (n.d.). Global Medical Isotope Supply Chain Program. Retrieved from https://www.energy.gov/ne/medical-isotopes

[4] World Nuclear Association. (2020). Medical Radioisotopes. Retrieved from https://www.world-nuclear.org/information-library/non-power-nuclear-applications/medicine/medical-radioisotopes.aspx

[5] National Public Radio. (2016, March 31). Canada's Nuclear Reactor Shutdown Threatens Medical Imaging Supplies Worldwide. Retrieved from https://www.npr.org/sections/health-shots/2016/03/31/472586705/canadas-nuclear-reactor-shutdown-threatens-medical-imaging-supplies-worldwide

[6] MarketsandMarkets. (2023). Radiopharmaceuticals Market - Global Forecast to 2028.

[7] International Atomic Energy Agency. (2020). Status and Prospects for Accelerator-Based Mo-99 Production. IAEA.